The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1249
Rasagiline (Azilect) for Parkinson's Disease
The full article is available to subscribers Subscriber Login   

Rasagiline (Azilect – Teva), a monoamine oxidase-type B (MAO-B) inhibitor, was recently approved by the FDA for once-daily oral treatment of Parkinson’s disease (PD). It can be taken alone for treatment of early disease or with levodopa/carbidopa (Sinemet, and others) for advanced disease. Selegiline (Eldepryl, and others), the first MAO-B inhibitor marketed in the US, has been available since 1988; a new lower-dose disintegrating tablet (Zelapar) was recently approved.

DRUGS FOR PARKINSON’S DISEASE — PD is characterized by loss of dopamine-containing neurons in the substantia nigra. Levodopa/carbidopa is considered the most effective treatment, but after 2 to 5 years, most patients develop motor complications including dyskinesias and fluctuations in therapeutic response. Dopamine agonists such as pramipexole (Mirapex) or ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Rasagiline (Azilect) for Parkinson's Disease
Article code: 1249a
 Electronic, downloadable article - $25